Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
1.030
+0.020 (1.98%)
At close: Nov 4, 2024, 4:00 PM
1.070
+0.040 (3.88%)
After-hours: Nov 4, 2024, 5:34 PM EST

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.

It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.

The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences.

Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical, Inc.
Clearside Biomedical logo
Country United States
Founded 2011
IPO Date Jun 2, 2016
Industry Biotechnology
Sector Healthcare
Employees 30
CEO George Lasezkay

Contact Details

Address:
900 North Point Parkway, Suite 200
Alpharetta, Georgia 30005
United States
Phone 678 270 3631
Website clearsidebio.com

Stock Details

Ticker Symbol CLSD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001539029
CUSIP Number 185063104
ISIN Number US1850631045
Employer ID 45-2437375
SIC Code 2834

Key Executives

Name Position
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. President, Chief Executive Officer and Director
Charles A. Deignan Chief Financial Officer
Jenny R. Kobin Head of Investor Relations
Rick McElheny Senior Vice President of Corporate Development and Alliance Management
Rafael V. Andino Senior Vice President of Engineering and Manufacturing
Susan L. Coultas Ph.D. Chief Clinical Officer
Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. Chief Medical Officer
Leslie B. Zacks Secretary

Latest SEC Filings

Date Type Title
Oct 9, 2024 8-K Current Report
Aug 12, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Jul 24, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
May 10, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 10, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material